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N E U R O S C I E N C E
Imaging striatal dopamine release using  
a nongenetically encoded near infrared fluorescent 
catecholamine nanosensor
Abraham G. Beyene1, Kristen Delevich2,3, Jackson Travis Del Bonis-O’Donnell1, David J. Piekarski1, 
Wan Chen Lin2, A. Wren Thomas3, Sarah J. Yang1, Polina Kosillo4, Darwin Yang1,  
George S. Prounis3, Linda Wilbrecht2,3*, Markita P. Landry1,3,5,6*
Neuromodulation plays a critical role in brain function in both health and disease, and new tools that capture neuro-
modulation with high spatial and temporal resolution are needed. Here, we introduce a synthetic catecholamine 
nanosensor with fluorescent emission in the near infrared range (1000–1300 nm), near infrared catecholamine 
nanosensor (nIRCat). We demonstrate that nIRCats can be used to measure electrically and optogenetically evoked 
dopamine release in brain tissue, revealing hotspots with a median size of 2 µm. We also demonstrated that nIRCats 
are compatible with dopamine pharmacology and show D2 autoreceptor modulation of evoked dopamine release, 
which varied as a function of initial release magnitude at different hotspots. Together, our data demonstrate that nIRCats 
and other nanosensors of this class can serve as versatile synthetic optical tools to monitor neuromodulatory 
neurotransmitter release with high spatial resolution.
INTRODUCTION
The catecholamines dopamine (DA) and norepinephrine (NE) are 
neuromodulators known to play an important role in learning and 
attention and are implicated in multiple brain disorders (1–5). DA, in 
particular, is thought to play a critical role in learning (6), motiva-
tion (7, 8), and motor control (9), and aberrations in DA neuro-
transmission are implicated in a wide range of neurological and 
psychiatric disorders including Parkinson’s disease (10), schizophrenia 
(11), and addiction (12).
Modulatory neurotransmission is thought to occur on a broader 
spatial scale than classic neurotransmission, the latter of which is 
largely mediated by synaptic release of the amino acids glutamate 
(GLU) and -aminobutyric acid (GABA) in the central nervous sys-
tem. In synaptic glutamatergic and GABAergic neurotransmission, 
neurotransmitter concentrations briefly rise in the synaptic cleft to 
mediate local communication between the pre- and postsynaptic 
neurons through the rapid activation of ligand-gated ion channels 
(13). In contrast, neuromodulators (catecholamines and neuropep-
tides) may diffuse beyond the synaptic cleft and act via extrasynap-
tically expressed metabotropic receptors (14–19). Thus, modulatory 
neurotransmitter activity extends beyond single synaptic partners 
and enables small numbers of neurons to modulate the activity of 
broader networks (20). The absence of direct change in ionic flux 
across cell membranes, which is measurable using available tools such 
as electrophysiology or genetically encoded voltage indicators, has 
necessitated the use of methods borrowed from analytical chemis-
try such as microdialysis and amperometry to study the dynamics 
of neuromodulation. However, the spatial limitations of fast-scan 
cyclic voltammetry (FSCV) and spatial and temporal limitations of 
microdialysis narrow our ability to interpret how neuromodulators 
affect the plasticity or function of individual neurons and synapses.
To understand how neuromodulation sculpts brain activity, we 
sought to develop new tools that can optically report modulatory 
neurotransmitter concentrations in the brain extracellular space (ECS) 
in a manner that is compatible with pharmacology and other avail-
able tools to image neural structure and activity. To this end, we 
designed a synthetic optical probe that can report extracellular cat-
echolamine dynamics with high spatial and temporal fidelity within 
a unique near infrared (nIR) spectral profile. nIR fluorescent, polymer- 
functionalized semiconducting single-wall carbon nanotubes 
(SWNTs) provide a versatile platform for optical probe synthesis to 
image a diverse set of biomolecular analytes, several of which have 
shown in vivo functionality (21–23). In this work, we describe the 
design, characterization, and implementation of a nanoscale nIR 
nongenetically encoded fluorescent reporter that allows precise 
measurement of catecholamine dynamics in brain tissue. This tech-
nology makes use of an SWNT noncovalently functionalized with 
single-strand (GT)6 oligonucleotides to form the nIR catecholamine 
nanosensor (nIRCat). nIRCats respond to DA with F/F of up to 
24-fold in the fluorescence emission window of 1000 to 1300 nm (24), 
a wavelength range that has shown utility for noninvasive through-
skull imaging in mice (25).
First, we show in vitro characterization of the nanosensor’s spec-
ificity for the catecholamines DA and NE and demonstrate its relative 
insensitivity to the neurotransmitters GABA, GLU, and acetylcholine 
(ACH), as well as the neuromodulators histamine, serotonin, tyramine, 
and octopamine. Second, we demonstrate that nIRCats exhibit a 
fractional change in fluorescence that has the dynamic range and 
signal-to-noise ratio to report DA efflux in response to brief electrical 
or optogenetic stimulation of dopaminergic terminals. Next, we use 
optogenetic stimulation to demonstrate selectivity of the nIRCat 
nanosensor response to dopaminergic over glutamatergic terminal 
stimulation. In both stimulation contexts, we show that bath appli-
cation of D2-type DA receptor antagonist sulpiride and agonist 
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quinpirole modulates nIRCat signals in a manner consistent with 
predicted effects of presynaptic D2 autoreceptor manipulation. These 
latter experiments can resolve previously undetectable heterogeneity 
in D2 autoreceptor modulation of presynaptic DA release upon ex-
posure to sulpiride or quinpirole. Last, we show that the presence of 
a DA reuptake inhibitor yields a prolonged nIRCat fluorescent sig-
nal, indicating that the sensors report a change in the time course of 
DA diffusion and reuptake in striatal brain tissue. These data indi-
cate that nIRCats provide a unique synthetic tool compatible with 
pharmacology to interrogate the release, diffusion, and reuptake of 
neuromodulators in neural tissue.
RESULTS
A nIR DA and NE nanosensor
We report nIR fluorescent probes that enable imaging of synaptic 
and extrasynaptic catecholamines and their release and reuptake 
dynamics in the ECS of brain tissue. Using a previously established 
nanosensor generation platform (26, 27), synthetic biomimetic 
polymers were pinned onto the surface of intrinsically nIR fluo-
rescent SWNTs. The resulting noncovalent nanometer-scale conju-
gate produced the catecholamine-selective nIRCat (Fig. 1A). In 
in vitro solution phase experiments (see Materials and Methods), 
nIRCats exhibited a chirality-dependent maximal change in fluores-
cence (F/F) of up to 24 (Fig. 1, B and C) with a dynamic range of 
four orders of magnitude, reporting detectable fluorescence changes 
from 10 nM to 100 M DA concentration (fig. S1A). nIRCats were 
also sensitive to NE with a maximal response of ∆F/F = 35 and a similar 
dynamic range. We further found that nIRCats had an ~3-fold 
higher affinity for DA over NE (fig. S1A). nIRCats were insensitive 
to GABA, GLU, and ACH (Fig. 1C) and could report fluctuations in 
DA concentration in the presence of ascorbic acid, which is present 
in cerebrospinal fluid (fig. S1B). nIRCats were also insensitive to 
octopamine and tyramine, biogenic amines that act as neurotrans-
mitters within invertebrates (Fig. 1C and fig. S1, C and D) and differ 
from DA by a single hydroxyl group in the case of tyramine or by 
the placement of a single hydroxyl group in the case of octopamine 
(fig. S1, C and D). Single-molecule imaging revealed that nIRCat 
signal in response to repeated perfusions of 10 M DA was revers-
ible, an important feature for measuring neuromodulator transients 
(fig. S2). In previous work, we performed stochastic simulations that 
suggest that nIRCats have sufficient sensitivity to detect physiologi-
cally relevant fluctuations in DA concentration in brain tissue arising 
from the activity of a single dopaminergic terminal, which can briefly 
exceed concentrations of 1 M from the release site in a distance- 
dependent manner (28).
Imaging of electrical stimulation–evoked DA release 
in striatal brain tissue
To determine the efficacy of nIRCats for imaging DA in brain tis-
sue, we used brain slices from the dorsal striatum of the mouse. Given 
that the dorsal striatum is densely innervated by dopaminergic pro-
jections from the substantia nigra pars compacta (SNc) but lacks in-
nervation from neurons that release NE (29), we leveraged nIRCats 
capacity to serve as a DA sensor in the striatum. Most of the neu-
rons within the striatum are GABAergic medium spiny neurons 
(MSNs) with a minority fraction of interneuron populations that 
include GABAergic and cholinergic interneurons (30). Glutamatergic 
inputs from the cortex and thalamus are the major drivers of MSN 
activity, and dopaminergic terminals in close proximity to these 
inputs are thought to play an important role in modulating the activ-
ity of MSNs and plasticity at striatal synapses (31). Because of the 
composition of local axons, intrastriatal electrical stimulation is 
predicted to drive the release of a mix of neurotransmitter, includ-
ing GABA, GLU, ACH, and DA, but negligible amounts of other 
catecholamines such as NE.
Coronal mouse brain slices were prepared as described previously 
(32). Slices were subsequently incubated with artificial cerebrospinal 
fluid (ACSF) containing nIRCats (2 mg/liter) for 15 min to enable 
sensors to diffuse into the brain tissue (fig. S3A). Slices were subse-
quently rinsed to remove excess nIRCats and incubated in standard 
ACSF for another 15 min before imaging. Imaging of nIRCat fluo-
rescence modulation in dorsal striatum was accomplished with a 
custom-built visible and nIR microscope to enable serial imaging of 
both visible (400 to 750 nm) and nIR (750 nm to 1700 nm) wave-
lengths on the same detector (fig. S3B). The nIRCat loading protocol 
enabled even and widespread labeling of the coronal slices containing 
the dorsal striatum (fig. S3C). Using this method, Godin et al. (33) 
have found that SWNTs localize in ECS. For the imaging procedure, 
a 785-nm laser for excitation of nIRCats or mercury bulb for gener-
ating bright-field images was directed onto the back focal plane of 
an epifluorescence upright microscope, and imaging channels were 
selected using a sliding mirror. Serially, either bright-field or nIR 
images were collected on a Ninox VIS-SWIR 640 broadband camera 
(Raptor Photonics) with appropriate dichroic filters (see Materials and 
Methods) and a 60× water-dipping objective (Nikon) providing an 
Fig. 1. Synthesis and testing of nIRCats. (A) Schematic of optical catecholamine 
reporters, nIRCats. Pristine SWNTs are functionalized with (GT)6 oligonucleotides 
to generate turn-on optical reporters for DA and NE. (B) Fluorescence spectra of 
nIRCats before (black) and after (red) the addition of 10 M of DA in an in vitro 
preparation in phosphate-buffered saline (PBS; without tissue). Multiple emission 
peaks correspond to unique SWNT chiralities contained within the multichirality 
mixture. a.u., arbitrary units. (C) Nanosensor optical response to 100 M DA, 
NE, GLU, GABA, ACH, serotonin (5-HT), histamine (HIST), octopamine (OCT), and 
tyramine (TYR) (data from in vitro testing). Black bars represent averages from 
n = 3 independent measurements, and error bars are calculated as SDs of the 
n = 3 measurements.
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imaging field of 178 m by 142 m, likely containing hundreds of 
dopaminergic terminals.
To investigate striatal neuromodulator release with temporal con-
trol of tissue stimulation, we used a bipolar stimulating electrode to 
evoke terminal release within the dorsomedial striatum of the mouse 
(stimulus protocol: 3-ms-wide single square pulses over five biological 
replicates). We found that a single pulse could elicit a nIRCat signal 
transient (Fig. 2A and movie S1) and that increasing the strength of 
the stimulus led to larger evoked changes in nIRCat F/F signal, 
(F/F)max [0.1 mA = 0.047 ± 0.025, 0.3 mA = 0.122 ± 0.026, and 
0.5 mA = 0.2 ± 0.033 (means ± SD); n = 5 for all measurements; 
P = 0.008 between 0.1 mA versus 0.3 mA and P = 0.008 between 
0.3 mA versus 0.5 mA; Fig. 2B]. Similar responses were additionally 
obtained in an ex vivo slice of a previously wild-caught species of 
mouse (Mus spicilegus) (fig. S4, A and B). We included M. spicilegus 
to illustrate the potential for nIRCat use in species not typically found 
in laboratories and in which surgical or genetic manipulation may 
be a barrier to measurement.
To further test whether evoked nIRCat signals in the mouse tracked 
striatal DA release and reuptake kinetics, we investigated the effect 
of nomifensine, a DA reuptake inhibitor that slows the clearance of 
DA from the ECS by competitively binding to DA transporters (DATs). 
The addition of 10 M nomifensine to the bath yielded nIRCat signal 
with higher peak fluorescence modulation [(∆F/F)max = 0.108 ± 0.029 
versus 0.189 ± 0.023 (means ± SD); n = 3; P = 0.0178] and a pro-
longed fluorescent signal compared to signals obtained in ACSF 
from the same field of view [decay time constant,  = 2.43 ± 0.24 s 
versus 10.95 ± 1.15 s (means ± SD); n = 3; P = 0.0002; Fig. 2, A (top 
versus bottom) and C]. Application of 0 mM extracellular Ca2+ ACSF 
abolished detectable nIRCat responses (P < 0.0001 relative to 2.5 mM 
Ca2+ ACSF), whereas 4 mM Ca2+ significantly enhanced evoked 
∆F/F transients (P < 0.0001; Fig. 2D), confirming that nIRCat sig-
nals reflect a calcium-dependent process.
To identify nIRCat fluorescence change hotspots (i.e., regions of 
high ∆F/F), we analyzed our video-rate acquisitions using a custom- 
built program that accounted for background fluorescence and 
identified regions with fluctuations in fluorescence intensity in the 
post-stimulation epoch (see Materials and Methods). We defined 
nIRCat ∆F/F hotspots as regions of interest (ROIs) based on a per-pixel 
stack projection of maximal ∆F/F in the imaging time series. Using 
data from single-pulse electrical stimulation experiments, we used 
custom software that identified ROIs whose sizes varied from 1 to 
15 m, with a log-normal distribution and a median ROI size of 2 m 
(Fig. 2, E and F). Repeat stimulations with the same stimulation am-
plitude in fields of view of the dorsomedial striatum across biological 
replicates generated similar size distributions (fig. S5A). We found 
that ∆F/F hotspots do not necessarily correspond to high nIRCat 
labeling of the brain tissue, suggesting that the hotspots are a conse-
quence of variation in DA release and not nanosensor loading in the 
tissue (fig. S5, B to F). Closer examination of several larger ROIs (>5 m) 
suggested that these may be composed of smaller hotspots in close 
proximity (Fig. 2G and fig. S5, B and C).
For further examination of the temporal resolution of nIRCats, 
we compared the temporal profile of evoked transients measured 
with nIRCats to transients measured with FSCV. FSCV is a tech-
nique that has been widely used to measure temporal catecholamine 
dynamics both in vivo and in vitro in the striatum and other brain 
areas (34–36). FSCV and nIRCat experiments were conducted on 
separate experimental rigs with the same solutions, temperature 
settings, electrodes, and stimulation parameters. Evoked transients 
measured with FSCV (fig. S5G) and nIRCat fluorescence emission 
showed comparable temporal profiles in the rising phase [latency to 
peak: FSCV = 0.25 ± 0.0 s versus nIRCat = 0.40 ± 0.18 s (means ± SD); 
n = 4 fields of view from two biological replicates; P = 0.23]. Mean-
while, nIRCat signals exhibited a wider diversity of decay kinetics 
[: FSCV = 0.51 ± 0.08 s versus nIRCats = 2.43 ± 0.24 s (means ± SD); 
n = 4 fields of view from two biological replicates; P = 0.0002). A 
subset of ROIs exhibited decay time constants that overlapped with, 
or were faster than, those of FSCV signals (Fig. 2, H and I).
We next evaluated the ability of nIRCats to detect DA in the 
presence of DA receptor drugs. First, using in vitro solution phase 
experiments (without biological tissue), we found that nIRCat fluo-
rescence intensity was not modulated by exposure to 1 M concentra-
tion of D2 receptor (D2R) antagonists sulpiride and haloperidol, the 
D2R agonist quinpirole, or the D1R antagonist SCH 23390 (Fig. 3A). 
Furthermore, with these in vitro solution phase experiments, we 
showed that DA-induced nIRCat fluorescence signals were not 
altered in the presence of these same drugs. These data confirmed 
that nIRCats retained their functionality in the presence of drugs 
that serve as DA receptor (DAR) agonists and antagonists (Fig. 3A).
We next moved to brain slice where presynaptic DA autorecep-
tors are known to play a critical role in regulating DA release. In the 
dorsal striatum of acute slices from n = 3 biological replicates, we 
found that a D2R agonist suppressed nIRCat transients while a 
D2R antagonist enhanced them (Fig. 3B). Application of quinpirole 
(1 M) suppressed nIRCat fluorescent transients in response to single- 
pulse electrical stimulation, which recovered following 15-min drug 
washout (Fig. 3, C and D). Conversely, application of sulpiride (1 M) 
significantly increased nIRCat ∆F/F (Fig. 3, E and F). The effects of 
these agonists and antagonists were present in ex vivo brain tissue, 
while they were absent in in vitro solution phase experiments above. 
Our results are therefore consistent with the powerful inhibition of 
presynaptic DA release by the D2R agonist quinpirole and the facil-
itation of presynaptic DA release by the D2R antagonist sulpiride.
Optical recording capability and nanoscale size of nIRCats en-
ables investigation of DA dynamics and pharmacological manipu-
lation with higher spatial resolution than can be achieved using other 
tools. Therefore, we next examined the effects of quinpirole and 
sulpiride on individual ROIs (see Materials and Methods). We also 
used an intermediate dose to provide greater information about differ-
ential dose response. We again used electrical stimulation in the dorsal 
striatum to drive DA release and compared the effect of quinpirole 
before and after bath application of the drug. We focused on ROIs 4 m 
or smaller to capture most of the ROIs while excluding the long tail 
of larger ROIs that are likely to contain many dopaminergic synapses 
(Fig. 2, F and G). Averaging all active ROIs 4 m or smaller, a high 
(1 M) concentration of quinpirole yielded post-drug to pre-drug 
∆F/F amplitude ratio of 0.48 ± 0.35 (Fig. 4, A and B). A lower concentration 
of quinpirole (0.25 M) resulted in an amplitude ratio of 0.91 ± 0.36 
(means ± SD of n = 150 ROIs identified within the field of view; 
Fig. 4, A and B). We repeated the experiment and analysis with bath 
application of sulpiride (1 M) and observed a sulpiride-induced 
amplitude ratio of 2.34 ± 1.3 (means ± SD of n = 150 ROIs within 
field of view; Fig. 4, D and E).
Analyses of individual ROIs (all smaller than 4 m) revealed hetero-
geneity in ROI responses upon bath application of either quinpirole 
or sulpiride. Notably, application of quinpirole preferentially sup-
pressed ROIs that exhibited higher ∆F/F before application of the 
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drug [Pearson correlation of r = −0.21 (P = 0.01) for 0.25 M data and 
r = −0.17 (P = 0.03) for 1 M data in Fig. 4C]. Additional quinpirole 
wash-on results are presented in figs. S6 (A to C) and S9. Conversely, 
our analysis showed that application of sulpiride enhanced nIRCat 
response in ROIs that had lower ∆F/F before application of the drug 
[Pearson correlation of r = −0.53 (P < 0.0001); Fig. 4F] (see addi-
tional data in fig. S6, D and F). Our work uncovers a statistically 
significant correlation between an ROI’s pre-drug ∆F/F amplitude 
and its post-drug response. It is possible that the observed heteroge-
neity in ROI responses maps onto variation in D2 autoreceptor 
Fig. 2. Imaging and spatiotemporal analysis of DA release evoked by electrical stimulation in striatal tissue. (A) Repeat images of the same field of view and 
F/F of nIRCat signal after electrical stimulation of 0.3 mA in standard ACSF (top) and in ACSF and 10 M nomifensine (bottom, +Nomifensine). Three example still frames 
are presented: “pre” is before electrical stimulation is applied, “stim” represents frame corresponding to peak ∆F/F following stimulation, and “post” is a frame after nIRCat 
fluorescence has returned to baseline. Scale bars, 10 m. (B) Nanosensor fluorescence modulation scaled with single-pulse electrical stimulation amplitudes. Field-of-view 
mean traces and SD bands are presented for three stimulation amplitudes of 0.1, 0.3, and 0.5 mA. (C) Time traces of ∆F/F for 0.3-mA single-pulse electrical stimulation in 
standard ACSF (red) and in ACSF and 10 M nomifensine (purple, +NOMF). Mean traces with SD bands are presented. (D) nIRCat ∆F/F responses are abolished in 0 mM 
Ca2+ ACSF and vary with extracellular (Ca2+). (E) A single frame from a time series gathered in the dorsomedial striatum showing the entire field of view, overlaid with 
regions of interest (ROIs) identified using per-pixel ∆F/F stack projections of nIRCat fluorescence modulation (see Materials and Methods). Color bar represents nIRCat 
labeling fluorescence intensity. Scale bar, 20 m. (F) Frequency histogram of ROI sizes depicted in (E), exhibiting a log-normal distribution with a median ROI size of 2 m. 
(G) A higher magnification view of an ROI with an effective radius of 5 m. Maximum ∆F/F projection of the ROI shows the presence of smaller fluorescence hotspots 
within the ROI. Scale bar, 5 m. (H) Overlay of representative normalized FSCV (gray) and nIRCat (blue) traces showing that nIRCat ROI signals exhibit heterogeneity in 
decay kinetics. Inset: An example of nIRCat experimental data (blue dots) fitted to first-order decay kinetics (red line) to compute decay time constants (). (I) Normalized 
frequency histogram of s computed from FSCV and nIRCat individual ROI time traces. Data from n = 4 fields of view representing n = 2 biological replicates were pooled. 
Medians of each distribution:  = 1.1 s (nIRCats) and  = 0.4 s (FSCV).
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expression and/or function (37–40), but further characterization will 
be necessary to confirm this hypothesis.
Imaging of optogenetically evoked DA release  
in striatal tissue
To further confirm that striatal nIRCat nanosensor signals were 
reporting DA release, we compared channelrhodopsin (ChR2) 
stimulation of cortical glutamatergic and nigrostriatal dopaminergic 
terminals in the dorsal striatum. Acute striatal brain slices were pre-
pared from mice virally transfected to express the light-sensitive 
cation channel ChR2 in either glutamatergic terminals of the stria-
tum [targeted by viral injection in the frontal cortices (ChR2-GLU); 
Fig. 5A and fig. S7, A and B] or dopaminergic terminals [targeted 
by viral injection in the midbrain in DAT-Cre mice (ChR2-DA); 
Fig. 5C and fig. S7C]. Upon optical stimulation of ChR2-DA termi-
nals with a 473-nm laser (five pulses at 25 Hz, 1 mW/mm2) in the 
dorsal striatum, we observed significant fluorescence modulation of 
nIRCat signal (Fig. 5D and movie S2). In contrast, when optogenetic 
stimulation was targeted at cortical glutamatergic terminals in the 
striatum, fluorescent nIRCat signals did not rise above baseline 
fluctuation. Notably, we could confirm in control experiment that 
optogenetic stimulation of cortical glutamatergic terminals was able 
to evoke excitatory postsynaptic currents in striatal MSNs (Fig. 5B, 
inset, and fig. S7, D and E).
Returning to ChR2-DA stimulation, we next varied the number 
of stimulation pulses (5-ms pulse duration, 25 Hz, 1 mW/mm2) and 
observed scaling in nIRCat ∆F/F amplitude from 1 to 10 pulses 
(P = 0.005) and trend level differences between 1 and 5 pulses 
(P = 0.0645) and between 5 and 10 pulses (P = 0.086; Fig. 5E). When 
we varied the pulse frequency while holding the number of pulses 
Fig. 3. Imaging DA release in the presence of DA receptor agonists and antagonists. (A) In vitro solution phase maximal ∆F/F (amplitude change at ~1128 nm) of 
nIRCat in the presence of 100 µM DA; the D2R antagonists sulpiride and haloperidol; D2R agonist quinpirole, and D1R antagonist SCH 23390; and drugs and DA. 
The addition of 1 M drug quantities did not induce nIRCat fluorescence modulation in the absence of DA (****P < 0.0001 compared to DA ∆F/F). Subsequent addition 
of DA to drug-incubated nIRCat solutions produced ∆F/F responses indistinguishable from DA-only responses. Error bars represent SDs from n = 3 measurements. n.s., not 
significant. (B) Top: A schematic of the effect of D2R agonist and antagonist drugs on DA release. Bottom: Quinpirole suppressed nIRCat fluorescence modulation 
(****P < 0.0001), whereas sulpiride facilitated nIRCat fluorescence (***P = 0.001) in n = 3 biological replicates. Individual data point represents (∆F/F)max ratio of the average 
trace collected in same field of view (post-/pre-drug application). (C and D) In brain slice, quinpirole (1 M) suppressed nIRCat fluorescence modulation in response to a 
single-pulse electrical stimulation (0.5 mA, 3 ms; red trace) compared to pre-drug ACSF (black trace) but recovered following drug washout (purple and orange traces). (E and 
F) Sulpiride (1 M) enhanced nIRCat fluorescence modulation in response to single-pulse electrical stimulation, yielding brighter nIRCat ∆F/F hotspots compared to drug-free 
ACSF. Scale bars, 10 m. All error bands in (C) and (E) represent SD from the mean trace.
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constant at five, we observed scaling with significant differences de-
tectable between 1 and 10 Hz (P = 0.036). The amplitude difference 
between 10 and 25 Hz did not reach significance (P = 0.179; Fig. 5F). 
In single-pulse experiments in which we varied pulse width, nIRCat 
fluorescence responses scaled with pulse duration. This effect was 
significant when comparing 2 to 5 ms (P = 0.002), but the difference 
from 5 to 10 ms did not reach significance (P = 0.055; Fig. 5G).
Last, we tested the effect of dopaminergic pharmacological agents 
on optogenetically evoked DA release (ChR2-DA). Bath application 
of quinpirole (1 M) powerfully suppressed nIRCat fluorescence 
(P < 0.0001), and this effect was reversed after drug washout (Fig. 5H). 
Consistent with results from electrical stimulation, optogenetic stim-
ulation also showed that quinpirole preferentially suppressed the 
most active ROIs (fig. S8). Nomifensine (10 M) enhanced nIRCat 
signal decay time, consistent with the predicted slowing of DA clear-
ance from the ECS (fig. S9).
DISCUSSION
To understand how neuromodulation alters the plasticity and activ-
ity of distinct populations of neurons, there is a need for new optical 
tools that can measure the extracellular dynamics of neuromodulator 
release and reuptake at spatiotemporal resolution commensurate 
with methods used to record neural activity (e.g., electrophysiology 
and calcium imaging). Here, we demonstrated the feasibility of using 
a nongenetically encoded fluorescent sensor, nIRCat, to enable optical 
detection of catecholamine release and reuptake with subsecond 
temporal and micrometer spatial resolution. We used electrical 
and optogenetic methods in striatal brain tissue to demonstrate that 
nIRCat fluorescent signals faithfully report evoked DA release and 
pharmacologically induced changes in DA dynamics.
We focused nIRCat imaging experiments within the dorsal stri-
atum, a region that receives dense dopaminergic innervation and 
negligible norepinephrinergic innervation (29). Therefore, while nIRCats 
may not be selective for DA over NE, nIRCats effectively function 
as a DA sensor within the context of the striatum. Given that striatal 
DA regulates fundamental processes, including motor function, 
motivation, and learning, nIRCats represent an important addition 
to the neuroscience investigative toolkit. Furthermore, of the biogenic 
amines present in invertebrate species (DA, tyramine, octopamine, 
serotonin, and histamine), we demonstrated in vitro that nIRCats 
are exclusively sensitive to DA. Hence, for invertebrate species such 
as drosophila, we predict that nIRCats may serve as selective and 
highly sensitive DA sensors throughout the brain.
While other tools are emerging to optically report DA fluctua-
tions via cell surface–engineered proteins (41, 42), nIRCats are likely 
to fulfill a niche among currently available methods for detecting DA 
neurotransmission because of their unique nIR fluorescence, the 
fact that they do not rely on genetic delivery and expression, their 
relative ease of deployment, and their functionality in the presence 
of pharmacological DA receptor ligands. This is in contrast to 
receptor-based fluorescent sensors, which currently cannot report 
on endogenous DA dynamics in the presence of ligands to the engi-
neered receptor but do exhibit selectivity for DA over NE (41, 42). 
Furthermore, the synthetic nature of nIRCats eliminates concern 
about potential G protein–coupled receptor–mediated residual sig-
naling that may be present in protein-based optical probes. nIRCats 
also offer spatial advantages over FSCV, and our initial experiments 
suggest that the temporal resolution of the nIRCat signal can be 
comparable to that of FSCV. nIRCat fluorescence decay profiles 
exhibit a wider temporal range than that observed from FSCV data 
and included a significant number of ROIs that showed seconds- long 
Fig. 4. Effects of quinpirole and sulpiride on nIRCat response at the level of ROIs (4 m or smaller). (A) ∆F/F of ROIs in ACSF and in ACSF with 0.25 M and 1 M of 
quinpirole. Each ∆F/F data point corresponding to an ROI is an average from n = 3 stimulation repeats. (B) Distribution of nIRCat response attenuation upon the addition 
of 0.25 M (blue) or 1 M (red) quinpirole for ROIs in (A). (C) Scatter plot of response to drug versus pre-drug ∆F/F amplitude for data in (A). (D) ∆F/F of ROIs in ACSF and 
following the addition of 1 M of sulpiride. Each ∆F/F data point corresponding to an ROI is an average from n = 3 stimulation repeats. (E) Distribution of post-to-pre drug 
∆F/F ratio for data in (D). (F) Scatter plot of response to drug versus pre-drug ∆F/F amplitude for data in (D). For (A) and (D), means and error bars (SD) are presented next 
to each distribution.
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time constants in addition to time constants faster than those measured 
by FSCV. It is debatable whether these results capture the unique spatial 
properties of specific striatal ROIs or are related to tool differences 
alone. nIRCats should also sample catecholamine concentration at a 
smaller spatial scale compared to FSCV. Each distributed nIRCat con-
struct can act as a probe within the ECS and therefore yield a “higher 
resolution” picture of neuromodulatory dynamics. Future experiments 
will investigate how the heterogeneity of nIRCat signals (amplitude, 
kinetics, and modulation by drugs) relates to structural and func-
tional properties at DA terminals and within the ECS. We predict 
that new optical tools for measuring DA dynamics with high spatial 
resolution will enable new insights into the regulation of DA release 
and reuptake at the level of individual synapses (43–45).
Furthermore, we see potential for future expansion of a larger 
family of SWNT-based nIR nanosensors (nIRNSs) similar to nIRCats 
for multiple neurochemical imaging applications. Several lines of 
evidence illustrate their future potential. First, nIRNSs are easily 
functionalized with a wide range of synthetic molecular recognition 
moieties, affording fine control of their surface functional elements and 
their interactions with the local chemical environment (22, 46, 47). 
SWNT fluorescence can be finely tuned to monochromatic emission 
in the nIR II window (1000 to 1700 nm) by controlling the SWNT 
chirality (48). This chirality-dependent fluorescence in the nIR II 
window provides further avenues for simultaneously designing color- 
specific responses to multiple molecular analytes, thereby affording 
synthesis of ratiometric and multiplexed analyte imaging platforms, 
as we have shown previously (49). Second, SWNT-based nanosen-
sors rely on nIR fluorescence, which greatly reduces the impact of 
tissue scattering in the emission window and therefore may enable 
through-cranium imaging (25). nIRNSs are compatible with multi-
photon imaging with an excitation of 1600 nm (50) and, as such, 
could permit nanoscale imaging of intact neuronal structures pend-
ing parallel developments in all-infrared microscopy, as has been 
shown with visible wavelength-emitting fluorophores (51). Third, 
nIRNSs exhibit robust nonphotobleaching photostability, allow-
ing their use in long-term imaging experiments (52). Fourth, 
because nIRNSs are not genetically encoded, they could enable 
use in species where gene delivery and protein expression are 
intractable, time- consuming, or undesirable. Last, the nanosecond- 
scale binding kinetics and nanoscale dimensions of nIRNSs are 
likely to enable generation of other neuromodulator nanosen-
sors with improved temporal and spatial resolution. In summary, 
nIRCats are versatile catecholamine probes amenable to multiplex-
ing with existing tools for concurrent investigation of dopami-
nergic neuromodulation with other core mechanisms of brain 
function.
MATERIALS AND METHODS
Nanosensor synthesis
(GT)6 oligonucleotides were purchased from Integrated DNA 
Technologies (standard desalting). HiPco SWNTs were purchased 
from NanoIntegris (batch no. HR27-104). (GT)6-SWNT colloidal 
suspension (nIRCat) was prepared by mixing 1 mg of (GT)6 and 
1 mg of SWNTs in 1 ml of a 100 mM NaCl solution. The solution was 
bath-sonicated (Branson Ultrasonic 1800) and probe tip-sonicated 
(Cole-Parmer Ultrasonic Processor, 3-mm tip in diameter, 5 W power) 
for 10 min each in an ice-bath.  The sonicated solution was incubated 
at room temperature for 30 min. The product was subsequently 
centrifuged at 16,000g (Eppendorf 5418) for 90 min to remove un-
suspended SWNT bundles and amorphous carbon, and the super-
natant was recovered for characterization and use. Each nanosensor 
suspension was stored at 4°C until use.
Fig. 5. nIRCat detection of striatal DA release evoked by optogenetic stimulation. 
(A) Schematic of ChR2 expression in cortical glutamatergic terminals synapsing in 
the dorsal striatum. AMPA, -amino-3-hydroxyl-5-methyl-4-isoxazolepropionate; 
NMDA, N-methyl-d-aspartate; DAR, DA receptor. (B) No nIRCat fluorescence modu-
lation was observed after stimulation of glutamatergic terminals. Inset: GLU release 
was confirmed by excitatory postsynaptic current (EPSC) on MSN. (C) Schematic 
of ChR2 expression in nigrostriatal dopaminergic terminals of the dorsal striatum. 
(D) Stimulation of dopaminergic terminals resulted in nIRCat fluorescence mod-
ulation. Stimulation protocol in (B) and (D) was five pulses (5P) at 25 Hz and a power 
flux of 1 mW/mm2, and each pulse had a duration of 5 ms. (E) nIRCat ∆F/F in 
response to increasing number of pulses delivered at 25 Hz (5-ms pulse duration). 
(F) nIRCat ∆F/F in response to increasing pulse frequency (1, 10, and 25 Hz) of five 
pulses. Each pulse had a duration of 5 ms. (G) nIRCat ∆F/F in response to single 
pulses of 2-, 5-, and 10-ms duration. (H) Bath application of 1 M of quinpirole sup-
presses DA release and results in depressed nIRCat ∆F/F. Drug washout rescues DA 
release and nIRCat ∆F/F. All error bands represent SD from the mean trace.
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Nanosensor characterization
To characterize nIRCats after synthesis, the full visible and nIR ab-
sorption spectrum was taken for each nanosensor batch (UV-VIS-nIR 
spectrophotometer, Shimadzu UV-3600 Plus) or UV-VIS (Thermo 
Fisher Scientific Genesys 20). SWNT concentra tions of as-made 
nanosensor batches were determined using absorb ance at 632 nm 
(UV-VIS) with an extinction coefficient of  = 0.036 (mg/liter)−1 cm−1. 
Full spectrum absorbance measurements were made with UV-VIS-
nIR after dilution to an SWNT concentration of 5 mg/liter in 100 mM 
NaCl. For fluorescence spectroscopy, each sensor batch was diluted 
to a working concentration of 5 mg/liter in 100 mM NaCl, and ali-
quots of 198 l were placed in each well of a 96-well plate (Corning). 
Fluorescence measurements were obtained with a 20× objective on an 
inverted Zeiss microscope (Axio Observer D1) coupled to a Princeton 
Instruments spectrograph (SCT 320) and a liquid nitrogen–cooled 
Princeton Instruments InGaAs linear array detector (PyLoN-IR). A 
721-nm laser (Opto Engine LLC) was used as the excitation light 
source for all characterization experiments.
Neurotransmitter library and dopamine receptor  
drug screening
For neurotransmitter response screens, we collected the nIR fluo-
rescence spectrum from 198 l aliquots of nanosensor (an SWNT 
concentration of 5 mg/liter) before and after the addition of 2 l of 
10 mM solutions of each analyte neurotransmitter (for a 100 M 
final analyte concentration in each well of a 96-well plate). All neuro-
transmitter analytes were purchased from Sigma-Aldrich. Neurotrans-
mitter analytes were incubated for 5 min before taking post- analyte 
fluorescence measurements. Responses were calculated for the inte-
grated fluorescence count as ∆F/F0 = (F − F0)/F0, where F0 is the 
total fluorescence before analyte addition and F is the total fluores-
cence after analyte addition or for peak fluorescence change corre-
sponding to the (9, 4) SWNT chirality (center wavelength, ~1128 nm). 
All measurements were made in triplicate. Reported results are 
means ± SD of the triplicate measurements. All nIRCat nanosensor 
batches were tested for catecholamine responses before use for tissue 
catecholamine imaging. DA receptor drugs were purchased from Tocris 
Bioscience (quinpirole and sulpiride), Abcam (SCH 23390), and Sigma- 
Aldrich (haloperidol). nIRCat fluorescence modulation to DRDs was 
measured after the addition of 1 M drug quantities (final concen-
tration in well) in each well. Post-drug fluorescence spectra were 
taken after 5-min drug incubation. To measure nIRCat response to 
DA in the presence of drugs, DA aliquots were added to each drug- 
incubated well to obtain 100 M of DA, and post-DA fluorescence 
spectra were taken after an additional 5-min incubation period.
Nanosensor reversibility testing
A 1.5 glass coverslip was functionalized with 3-aminopropyltriethoxy-
silane (APTES; Sigma-Aldrich) by soaking in 10% APTES in ethanol 
for 5 min. The coverslip was then rinsed with deionized water and 
left to dry. The coverslip was then fixed onto an ibidi sticky-Slide VI 
0.4 forming six microfluidic channels. First, 100 l of phosphate- 
buffered saline (PBS) was pipetted through a channel. Next, the 
channel was filled with 50 l of a solution (5 mg/liter) of nIRCats 
and left to incubate at room temperature for 5 min. The channel 
was rinsed using three 50 l of PBS washes, keeping the channel 
filled with solution at all times. The surface-immobilized nIRCats in 
PBS were imaged on an epifluorescence microscope with an exci-
tation of 721 nm and a Ninox VIS-SWIR 640 camera (Raptor). One 
end of the flow channel was connected to a syringe pump (Harvard 
Apparatus) using Luer lock fittings. Before the start of image acqui-
sition, the opposite flow reservoir was filled with PBS, and the pump 
was set to refill mode at a volumetric flow rate of 40 l min−1. Once 
the liquid in the reservoir was depleted, 40 l of 10 M DA in PBS 
was added. The process was repeated using alternating additions of 
80 l of PBS washes and 40 l of DA solution.
Acute slice preparation and nanosensor labeling
Mice were C57BL/6 strain (60 days old), and both male and female 
mice were used. Mice were group-housed after weaning at postnatal 
day 21 (P21) and kept with nesting material on a 12:12 light cycle. 
All animal procedures were approved by the University of California 
Berkeley Animal Care and Use Committee. Acute brain slices were 
prepared using established protocols (32). Briefly, mice were deeply 
anesthetized via intraperitoneal injection of ketamine/xylazine cocktail, 
and transcardial perfusion was performed using ice-cold cutting buffer 
(119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 
3.5 mM MgCl2, 10 mM glucose, and 0 mM CaCl2), after which the 
brain was rapidly extracted. The cerebellum and other connective 
tissues were trimmed using a razor blade, and the brain was mounted 
onto the cutting stage of a vibratome (Leica VT1200 S). Coronal slices 
(thickness, 300 m) including the dorsal striatum were prepared. 
Slices were incubated at 37°C for 60 min in oxygen-saturated ACSF 
(119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 
1.3 mM MgCl2, 10 mM glucose, and 2 mM CaCl2) before use. Slices 
were then transferred to room temperature for 30 min before starting 
imaging experiments and were maintained at room temperature for 
the remainder of experimentation.
For nanosensor labeling, slices were transferred into a small volume 
brain slice incubation chamber (Scientific Systems Design Inc., AutoMate 
Scientific) and kept under oxygen-saturated ACSF (total volume, 
5 ml). One hundred microliters of nIRCat nanosensor (100 mg/liter) 
was added to the 5-ml volume, and the slice was incubated in this 
solution for 15 min. The slice was subsequently recovered and rinsed 
in oxygen-saturated ACSF to wash off nIRCats that did not localize 
into the brain tissue. The rinsing step was performed by transferring 
the slice through three wells of a 24-well plate (5 s in each well), fol-
lowed by transfer to the recording chamber with ACSF perfusion 
for a 15-min equilibration period before starting the imaging exper-
imentation. All imaging experiments were performed at 32°C.
Acute slice preparation for FSCV recording
Acute slices were prepared as described previously. Extracellular DA 
concentration evoked by local electrical stimulation was monitored 
with FSCV at carbon fiber microelectrodes (CFMs) using a Millar 
voltammeter. CFMs were ~7 m in diameter encased in glass capil-
lary pulled to form a seal with the fiber and cut to final tip length of 
70 to 120 m. The CFM was positioned ~100 m below the tissue 
surface at a 45° angle. A triangular waveform was applied to the CFM 
scanning from −0.7 to +1.3 V and back, against Ag/AgCl reference 
electrode at a rate of 800 V/s. Evoked DA transients were sampled 
at 8 Hz, and data were acquired at 50 kHz using AxoScope 10.5 
(Molecular Devices). Oxidation currents evoked by electrical stim-
ulation were converted to DA concentration from post-experimental 
calibrations. Recorded FSCV signals were identified as DA by com-
paring oxidation (+0.6 V) and reduction (−0.2 V) potential peaks 
from experimental voltammograms with currents recorded during 
calibration with 2 M DA dissolved in ACSF. For stimulation, a 
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bipolar stimulation electrode (FHC CBAEC75) was positioned on 
top of the brain slice and approximately 100 m away from the 
CFM. Following 30-min slice equilibration in the recording chamber, 
DA release was evoked using a square pulse (pulse amplitude, 0.3 mA; 
pulse duration, 3 ms) controlled by an ISO-Flex stimulus isolator 
(A.M.P.I) and delivered out of phase with the voltammetric scans. 
Stimulation was repeated three times. To compare FSCV and nIRcat 
data, each signal was normalized against its peak value [(DA)max or 
(∆F/F)max] and coaligned at stimulation time. Latency to peak was 
computed as tpeak − tstim, where tpeak is the time at which peak signal 
is attained, and tstim is time of stimulation. Decay time constants () 
were computed from model fits to a first-order decay process.
Microscope construction and slice imaging
Ex vivo slice imaging was performed with a modified upright epiflu-
orescent microscope (Olympus, Sutter Instruments) mounted onto a 
motorized stage. Nanosensor excitation was supplied by a 785-nm 
CW DPSS (continuous-wave diode-pumped solid-state) laser with 
adjustable output power to a maximum of 300 mW and a near TEM00 
top hat beam profile (Opto Engine LLC). The beam was expanded 
using a Keplerian beam expander composed of two plano-convex 
lenses ( f = 25 and 75 mm; AR coating B, Thorlabs) to a final beam 
diameter of approximately 1 cm. The beam was passed through a 
custom fluorescence filter cube [excitation: 800 nm shortpass 
(FESH0800), dichroic: 900 longpass (DMLP990R), and emission: 
900 longpass (FELH0900); Thorlabs] to a 60× Apo objective (nu-
merical aperture, 1.0; working distance, 2.8 mm; water dipping; 
high nIR transmission; Nikon CFI Apo 60XW nIR). Emission pho-
tons collected from the sample were passed through the filter cube, 
were focused onto a two-dimensional InGaAs array detector [500 to 
600 nm: 40% quantum efficiency (QE); 1000 to 1500 nm: >85% QE; 
Ninox 640, Raptor Photonics], and were recorded using the Micro- 
Manager Open Source Microscopy Software (53). Laser power was 
adjusted to maximize collected photons and to fill the pixel bit depth 
on the detector but did not exceed 70 mW at the objective back focal 
plane. Yellow fluorescent protein (YFP) was imaged by switching the 
filter cube (U-N41017XL, Olympus) and by using a mercury-vapor 
lamp (Olympus) for excitation.
Electrical and optical stimulation–evoked DA imaging 
with nIR microscopy
For electrical stimulation experiments, a bipolar stimulation elec-
trode was positioned in field of view within the dorsomedial striatum 
identified using a 4× objective (Olympus XLFluor 4×/340). Using 
60× objective, the stimulation electrode was brought into contact with 
top surface of the brain slice and an imaging field of view was cho-
sen at a nominal distance of 150 m from the stimulation electrode 
within the dorsomedial striatum. All stimulation experiments were re-
corded at video frame rates of 9 frames per second (nominal), and 
single-pulse electrical stimulations were applied after 200 frames of 
baseline were acquired. Each video acquisition lasted 600 frames. 
Stimulation amplitudes were staggered, and each stimulation am-
plitude was repeated three times within a field of view. Slices were 
allowed to recover for 5 min between each stimulation, with the ex-
citation laser path shuttered. For optogenetic stimulation, a fiber- 
coupled 473-nm blue laser (Opto Engine LLC DPSS) was positioned 
in close proximity to the brain slice using a micromanipulator. Ex-
pression of ChR2 was confirmed via visible fluorescence imaging, 
and an imaging field of view was chosen in dorsomedial striatum 
with robust expression level. Stimulation pulses (five pulses, 5-ms du-
ration per pulse at 25 Hz, 1 mW/mm2) were delivered after acquiring 
200 baseline frames, and the video acquisition lasted 600 frames 
at nominal 9 frames per second. Drugs were bath-applied to the 
imaging chamber through ACSF perfusion. ACSF with 10 M of 
nomifensine or 1 M of each drug was used. When the effect of a 
drug was needed to be evaluated, stimulation/imaging experiments 
were carried out with drug-free ACSF in an imaging field of view to 
collect drug-free data. Normal ACSF was then switched to ACSF 
prepared with the drug of interest and applied for 10 min before 
stimulation/imaging experiments resumed.
Viral transfection of mice for optogenetic stimulation
Adult male and female mice (>P60) were used for all surgeries. Bi-
lateral viral injections were performed using previously described 
procedures (54) at the following stereotaxic coordinates: 1.94 mm 
from bregma, 0.34 mm lateral from midline, and 0.70 mm vertical 
from cortical surface for dorsomedial prefrontal cortex (dmPFC) and 
−3.08 mm from bregma, 1.25 mm lateral from midline, and 4.0 mm 
vertical from cortical surface for SNc. For glutamatergic corticostriatal 
axon stimulation experiments, mice were bilaterally injected with 
0.5 l of CAG-ChR2-EYFP (enhanced YFP) virus into dmPFC. For 
nigrostriatal dopaminergic axon stimulation experiments, DAT-Cre 
mice were injected with 0.5 l of DIO-ChR2-EYFP virus bilaterally. 
For all optogenetic experiments, we waited at least 3 weeks from viral 
injection to experimental stimulation to allow for sufficient ChR2 
gene expression.
To confirm that DA neurons were transfected with ChR2 in 
animals used for optogenetic DA stimulation experiments, we per-
fused DAT-Cre mice that had been injected into the SNc with Cre- 
dependent ChR2-EYFP virus with 4% paraformaldehyde in PBS 
and post-fixed brains overnight. Coronal sections that included the 
injection site (SNc) and imaging site (dorsal striatum) were cut at 50 M 
and immunolabeled using antibody against tyrosine hydroxylase 
[TH (1:1000); rabbit anti-TH, Millipore], the rate-limiting enzyme 
for catecholamine synthesis. Goat anti-rabbit DyLight 594 second-
ary antibody (1:1000; Invitrogen) was used to visualize TH. Image 
acquisition was performed on a Zeiss Axio ScanZ.1 using a 5× 
objective.
Image processing and data analysis of nIRCat  
fluorescence response
Raw movie files were processed using a custom-built MATLAB program 
(https://github.com/jtdbod/Nanosensor-Brain-Imaging). Briefly, for 
each raw movie stack (600 frames), a per-pixel ∆F/F defined as 
(F − F0)/F0 was calculated using the average intensity for the first 5% 
of frames as F0, and F represents the dynamic fluorescence intensity 
at each pixel. ROIs were identified by calculating a median filter 
convolution and then performing thresholding using Otsu’s method 
to identify ROIs with strong fluorescence modulation over back-
ground, followed by a morphological dilation operation. ∆F/F traces 
were then calculated for each generated ROI by averaging pixel values 
over the ROI. ROI sizes were computed using the measured pixel area 
and by approximating each as a circle to calculate an equivalent radius.
To compare responses across stimulation amplitudes and bath 
application of nomifensine, mean results were obtained as follows: 
First, all identified ROIs from a field of imaging were averaged. Mean 
traces were further averaged over different fields of view within the 
same slice and across slices (1 to 2 fields of view per slice and 1 to 
Beyene et al., Sci. Adv. 2019; 5 : eaaw3108     10 July 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
10 of 11
2 slices per animal) and then averaged over experimental animals. 
Decay time constants () were computed by fitting ∆F/F time traces 
to a first-order decay process on an ROI basis or field-of-view average 
basis. Latency to peak was computed as tpeak − tstim, where tpeak is the 
time at which peak signal is attained and tstim is time of stimulation. 
All statistical tests of significance (P values) were computed and re-
ported from unpaired two-tailed t test.
ROI-level analysis of drug washes were computed by generating 
an ROI mask from one of the triplicate stimulations and then com-
puting ∆F/F traces using the same ROI mask for all experimental 
runs (before and after application of drug). Each raw movie file was 
corrected for translational and rotational drift using StackReg plugin 
in FIJI and then processed using our custom MATLAB script. We 
removed all ROIs that were greater than 4 m in size for subsequent 
analysis. For each ROI, post-to-pre drug ratios were computed as 
(∆F/F)max-post-drug/(∆F/F)max-pre-drug. Here, we define (∆F/F)max as 
the amplitude of nIRCat response in the post-stimulation epoch. 
Mean values from triplicate stimulation were used to evaluate the ratio.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/7/eaaw3108/DC1
Fig. S1. nIRCats are compatible with concentrations and conditions expected in brain tissue.
Fig. S2. Surface-immobilized single nIRCats are reversible upon repeat exposure to DA.
Fig. S3. Brain slice nIRCat loading protocol and schematic of visible and nIR fluorescence 
microscopy for imaging nIRCats in brain tissue.
Fig. S4. nIRCat imaging in M. spicilegus brain tissue.
Fig. S5. Intensity of nIRCat labeling at baseline does not predict site of ∆F/F hotspots.
Fig. S6. Variability in effect of quinpirole and sulpiride on nIRCat response on spatially 
segregated ROIs within a field of view.
Fig. S7. Data that confirm targeting of optogenetic stimulation of dopaminergic and 
glutamatergic inputs to the striatum.
Fig. S8. Effect of quinpirole on ChR2 evoked nIRCat response at the level of ROIs.
Fig. S9. Nomifensine extends nIRCat response to ChR2 stimulation of dopaminergic terminals 
in the dorsal striatum.
Movie S1. A representative movie from single-pulse electrical stimulation (0.3 mA) in dorsal 
striatum.
Movie S2. A representative movie from optogenetic stimulation (five pulses at 25 Hz, 1 mW mm2) 
in dorsal striatum.
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